



[12] Patent

[11] Patent No.: GC 0000171	Number of the Decision to Grant the Patent: 5/966
[45] Date of Publishing the Grant of the Patent: 29/03/2006 5/2006	Date of the Decision to Grant the Patent: 02/07/2005
[21] Application No.: GCC/P/1999/111 [22] Filing Date: 03/04/1999 [72] Inventors: 1- Jean Stephenne, 2- Martine Anne Cecile Wettendorff [73] Owner: Smithkline Beecham Biologicals S.A., Rue de l'Institut 89, B-1330 Rixensart, Belgium [74] Agent: Hasan Al-Mulla	[51] Int. Cl. ⁷ : A61K 39/295, 39/39 [56] Cited Documents: - WO 92/11291 A (SMITHKLINE BEECHAM BIOLOGICALS S.A.) 09 July 1992 - "Construction of Live Vaccines Using Genetically Engineered Poxviruses; Biological Activity of Vaccinia Virus Recombinants Expressing the Hepatitis B Virus Surface Antigen and the Herpes Simplex Virus Glycoprotein D", Chemical abstract, Volume 100, No. 13, 26 March 1984 - "Vaccinia Virus Double Recombinant, Expressing The Hepatitis B Virus Surface Antigen and Herpes Simplex Virus Thymidine Kinase", Chemical abstract, Volume 105, No. 25, 22 December 1986

[54] NOVEL VACCINE FORMULATIONS, METHODS FOR PREPARING THEM AND THEIR USE IN THERAPY

[57] Abstract: Novel combined vaccine compositions preferentially for administration to adolescents are provided, comprising a hepatitis B viral antigen and a herpes simplex viral antigen and optionally in addition one or more of the following: an EBV antigen, a hepatitis A antigen or inactivated attenuated virus, a HPV antigen, a VZV antigen, a HCMV antigen, a Toxoplasma gondii antigen. The vaccine compositions are formulated with an adjuvant which is a preferential stimulator of TH1 cell response such as 3D-MPL and QS21.

No. of claims: 20

No. of figures: 7